A phase 1 clinical trial (NCT03198546) evaluating CAR-T cells with constitutive expression of IL-7 and CCL19 in six patients with progressive hepatocellular carcinoma, pancreatic carcinoma, and ovarian carcinoma expressing either GPC3 or MSLN showed promising results [84]. Here, MSLN is linked to ovarian carcinoma.